Insite Files New Drug Submission With Health Canada
Posted on: Tuesday, 4 December 2007, 12:00 CST
InSite Vision has filed a new drug submission with Health Canada seeking regulatory approval to market the topical ocular antibiotic AzaSite 1% for the treatment of bacterial conjunctivitis in Canada.
AzaSite was approved for bacterial conjunctivitis treatment by the FDA in April 2007, and was commercially launched in the US in August 2007 by Inspire Pharmaceuticals, AzaSite's exclusive licensee in the US and Canada.
InSite has granted exclusive rights to Inspire to commercialize AzaSite for the treatment of ocular infections in the US and Canada in exchange for milestone payments and royalties for products sold in both countries.
Kumar Chandrasekaran, president and CEO of InSite, said: "This second filing is an important step in AzaSite worldwide commercialization, and will enable our partner Inspire to expand sales of AzaSite beyond the borders of the US."
Source: Datamonitor
Related Articles
- Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
- InSite Vision Initiates Pivotal Phase 3 Trials for AzaSite Plus(TM)
- Inspire Licenses AzaSite(TM) For Ocular Infections
- BMO Donates $1 Million to Made-in-Canada AIDS Prevention/Treatment Model
- Oscient Pharmaceuticals and Abbott Canada Enter into Commercialization Agreement for FACTIVE Tablets; FACTIVE Launch in Canada for the Treatment of AECB Planned for Later This Year
- InSite Vision Announces Submission of AzaSite(TM) NDA
- InSite Vision Completes Enrollment in Second Phase 3 AzaSite(TM) Clinical Study
- InSite Vision Completes Enrollment In First Phase 3 AzaSite(TM) Clinical Study
- OSI Pharmaceuticals Announces Tarceva Granted Approval in Canada for the Treatment of Advanced Non-Small Cell Lung Cancer
 |
 |
User Comments (0)
RSS Feeds